Cardiol Therapeutics Inc. (CRDL) Form 6-K — Nov 3, 2026
Cardiol Therapeutics has entered into an at-the-market equity offering agreement with Jefferies LLC, giving it the ability to issue and sell common shares for up to US$75,000,000 in aggregate gross proceeds from time to time. Sales will be made in the United States at prevailing market prices under the company's Form F-10 registration statement and Canadian base shelf prospectus, both effective since September 2026 covering up to US$150 million of securities.
Key figures
- Gross Proceeds
- 75000000
- Offering type
- at-the-market (ATM) equity program
- Shelf capacity usd
- 150000000
- Shelf prospectus date
- September 15, 2026
- Maximum program amount usd
- 75000000
- Registration effective date
- September 16, 2026
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.